A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX.
Stroes CI, Schokker S, Molenaar RJ, Mathôt RAA, Bijlsma MF, van der Woude SO, Belo Pereira JP, Hooijer GKJ, Verhoeven RHA, Cats A, Grootscholten C, van Sandick JW, Creemers GJ, Nieuwenhuijzen GAP, Haj Mohammad N, Ruurda JP, Meijer SL, Hulshof MCCM, van Berge Henegouwen MI, van Laarhoven HWM.
Stroes CI, et al. Among authors: van sandick jw, van laarhoven hwm, van berge henegouwen mi, van der woude so.
Cancers (Basel). 2021 Feb 17;13(4):839. doi: 10.3390/cancers13040839.
Cancers (Basel). 2021.
PMID: 33671266
Free PMC article.